Comparable stake leader
ARCH Venture Fund X, L.P.
SEC ownership of Maze Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001842295.
Disclosed value leader
Third Rock Ventures IV, L.P.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- MAZE on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARCH Venture Fund X, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARCH Venture Fund X, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001842295
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Maze Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARCH Venture Fund X, L.P.
Disclosed value leader
Third Rock Ventures IV, L.P.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 9.4%
13D/G row: ARCH Venture Fund X, L.P.
Showing 1-8 of 50 holder rows.
Quick read
ARCH Venture Fund X, L.P. leads the comparable SEC ownership view at 9.4%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARCH Venture Fund X, L.P.'s linked filing trail.
Comparable ownership
Top 5
ARCH Venture Fund X, L.P.
9.4%
Third Rock Ventures IV, L.P.
9.3%
Deep Track Capital, LP
9%
Frazier Life Sciences Public Fund...
9%
Janus Henderson Group Ltd.
5.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P. |
13D/G
|
9.4%
|
$36,215,266
4,120,053 shares
|
$0 | 31 Mar 2025 |
| Third Rock Ventures IV, L.P. |
13D/G
3/4/5
10%+ Owner
|
9.3%
|
$179,808,372
4,473,958 shares
|
-$64,304,000 | 31 Dec 2025 |
| Deep Track Capital, LP |
13F
13D/G
Company
|
9%
from 13D/G
|
$111,379,859
3,732,569 shares
|
— | 30 Jun 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
9%
|
$174,515,671
4,342,266 shares
|
+$39,762,017 | 31 Dec 2025 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
5.8%
|
$78,390,380
2,858,876 shares
|
-$9,531,082 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.4%
from 13D/G
|
$104,524,775
3,502,841 shares
|
— | 30 Jun 2026 |
| Matrix Capital Management Company, LP |
13D/G
|
3.5%
|
$42,880,026
1,653,684 shares
|
-$21,586,725 | 30 Sep 2025 |
| GV 2019, L.P. |
13D/G
Alphabet Holdings LLC
|
2.9%
|
$57,528,994
1,388,583 shares
|
-$42,419,680 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$22,565,571.
Buys
$0
Insiders: 0
Sells
$22,565,571
Insiders: 7
Net
-$22,565,571
Shares: -672,473
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 672,473
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 253,818 | $0 | $6,911,208 | -$6,911,208 |
| 3-6 | 0 | 125,998 | $0 | $3,705,777 | -$3,705,777 |
| 6-9 | 0 | 271,913 | $0 | $11,484,551 | -$11,484,551 |
| 9-12 | 0 | 20,744 | $0 | $464,035 | -$464,035 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 23 reporting-owner rows connected to Maze Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
23
Largest Forms 3/4/5 holder
Third Rock Ventures IV, L.P.
Net 12M change
-$22,565,571
Latest report
04 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 10%+ Owner | $140,662,889 | Mixed | 04 Nov 2025 | ||
| Jason Coloma V | Chief Executive Officer, Director | $7,911,790 | -$5,254,500 | -40% | Mixed | 02 Sep 2026 |
| Charles J. Homcy | Director | $1,175,281 | Mixed | 08 Jun 2026 | ||
| Atul Dandekar | Csbo | $834,075 | -$5,012,201 | -86% | Filing P/S | 02 Sep 2026 |
| Amy Bachrodt | SVP, Finance | $393,315 | -$1,559,380 | -80% | Filing P/S | 01 Apr 2026 |
| Courtney Phillips | GC and Corp. Secretary | $180,640 | -$104,766 | -37% | Filing P/S | 02 Sep 2026 |
| Catherine A. Sohn | Director | $0 | -$1,149,054 | -100% | Mixed | 06 Jan 2026 |
| Harold Bernstein | President, R&D & CMO | $0 | -$9,021,635 | -100% | Mixed | 04 Sep 2026 |
| Richard H. Scheller | Director | $0 | -$464,035 | -100% | Mixed | 08 Jun 2026 |
| Jonathan E. Lim | Director | Mixed | 08 Jun 2026 | |||
| Misbah Tahir | Chief Financial Officer | Mixed | 02 Mar 2026 | |||
| Herve Hoppenot | Director | Mixed | 08 Jun 2026 | |||
| Neil Kumar | Director | Mixed | 27 Mar 2026 | |||
| Paula A. Johnson | Director | Mixed | 13 Aug 2026 | |||
| Sophie Kornowski | Director | Mixed | 13 Aug 2026 | |||
| Jeffrey K. Tong | Director | Mixed | 30 Jan 2025 | |||
| Sekar Kathiresan | Director | Mixed | 22 Sep 2025 | |||
| Daniel K. Spiegelman | Director | Mixed | 08 Jun 2026 | |||
| ARCH Venture Partners X, LLC | 10%+ Owner | Mixed | 30 Jan 2025 | |||
| Nancy C. Andrews | Director | Mixed | 08 Jun 2026 |
Recent insider transactions for Maze Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Harold Bernstein | MAZE | Common Stock | Sale | -100% | $254,502 | $26.22 | -9,705 | 0 | 04 Sep 2026 | Direct |
| Courtney Phillips | MAZE | Common Stock | Sale | -22.3% | $52,334 | $26.01 | -2,012 | 7,007 | 03 Sep 2026 | Direct |
| Atul Dandekar | MAZE | Common Stock | Sale | -9.12% | $84,354 | $26.01 | -3,243 | 32,316 | 03 Sep 2026 | Direct |
| Jason Coloma V | MAZE | Common Stock | Sale | -29.4% | $296,807 | $26.01 | -11,411 | 27,362 | 03 Sep 2026 | Direct |
| Harold Bernstein | MAZE | Common Stock | Sale | -34.8% | $134,969 | $26.01 | -5,189 | 9,705 | 03 Sep 2026 | Direct |
| Courtney Phillips | MAZE | Common Stock | Sale | -18% | $52,432 | $26.47 | -1,981 | 9,019 | 02 Sep 2026 | Direct |
| Atul Dandekar | MAZE | Common Stock | Sale | -8.23% | $84,457 | $26.47 | -3,191 | 35,559 | 02 Sep 2026 | Direct |
| Jason Coloma V | MAZE | Common Stock | Sale | -22.4% | $297,148 | $26.47 | -11,227 | 38,773 | 02 Sep 2026 | Direct |
| Harold Bernstein | MAZE | Common Stock | Sale | -25.5% | $135,142 | $26.47 | -5,106 | 14,894 | 02 Sep 2026 | Direct |
| Harold Bernstein | MAZE | Common Stock | Sale | -100% | $425,512 | $26.36 | -16,141 | 0 | 01 Sep 2026 | Direct |
| Harold Bernstein | MAZE | Common Stock | Options Exercise | 36,141 | 20,000 | 01 Sep 2026 | Direct | |||
| Harold Bernstein | MAZE | Restricted Stock Units | Options Exercise | -50% | -20,000 | 20,000 | 01 Sep 2026 | Direct | ||
| Harold Bernstein | MAZE | Stock Option (Right to Buy) | Options Exercise | -9.13% | -16,141 | 160,662 | 01 Sep 2026 | Direct | ||
| Courtney Phillips | MAZE | Common Stock | Options Exercise | 11,000 | 11,000 | 01 Sep 2026 | Direct | |||
| Courtney Phillips | MAZE | Restricted Stock Units | Options Exercise | -50% | -11,000 | 11,000 | 01 Sep 2026 | Direct | ||
| Atul Dandekar | MAZE | Common Stock | Options Exercise | 47.6% | 12,500 | 38,750 | 01 Sep 2026 | Direct | ||
| Atul Dandekar | MAZE | Restricted Stock Units | Options Exercise | -50% | -12,500 | 12,500 | 01 Sep 2026 | Direct | ||
| Jason Coloma V | MAZE | Common Stock | Options Exercise | 50,000 | 50,000 | 01 Sep 2026 | Direct | |||
| Jason Coloma V | MAZE | Common Stock | Sale | -12.5% | $838,785 | $26.29 | -31,908 | 223,355 | 01 Sep 2026 | Coloma Family Trust |
| Jason Coloma V | MAZE | Common Stock | Sale | -12.5% | $68,214 | $26.31 | -2,593 | 18,151 | 01 Sep 2026 | The Coloma 2021 Irrevocable Trust |
| Jason Coloma V | MAZE | Restricted Stock Units | Options Exercise | -50% | -50,000 | 50,000 | 01 Sep 2026 | Direct | ||
| Atul Dandekar | MAZE | Common Stock | Sale | -22.2% | $206,824 | $27.58 | -7,500 | 26,250 | 28 Aug 2026 | Direct |
| Atul Dandekar | MAZE | Common Stock | Options Exercise | 28.6% | 7,500 | 33,750 | 28 Aug 2026 | Direct | ||
| Atul Dandekar | MAZE | Stock Option (Right to Buy) | Options Exercise | -34.6% | -7,500 | 14,143 | 28 Aug 2026 | Direct | ||
| Sophie Kornowski | MAZE | Stock Option (Right to Buy) | Award | 36,000 | 36,000 | 13 Aug 2026 | Direct | |||
| Paula A. Johnson | MAZE | Stock Option (Right to Buy) | Award | 36,000 | 36,000 | 13 Aug 2026 | Direct | |||
| Harold Bernstein | MAZE | Common Stock | Sale | -100% | $445,621 | $27.61 | -16,142 | 0 | 13 Aug 2026 | Direct |
| Harold Bernstein | MAZE | Common Stock | Options Exercise | 16,142 | 16,142 | 13 Aug 2026 | Direct | |||
| Harold Bernstein | MAZE | Stock Option (Right to Buy) | Options Exercise | -8.37% | -16,142 | 176,803 | 13 Aug 2026 | Direct | ||
| Jason Coloma V | MAZE | Common Stock | Sale | -11.1% | $852,986 | $26.73 | -31,908 | 255,263 | 03 Aug 2026 | Coloma Family Trust |
| Jason Coloma V | MAZE | Common Stock | Sale | -11.1% | $69,329 | $26.74 | -2,593 | 20,744 | 03 Aug 2026 | The Coloma 2021 Irrevocable Trust |
| Atul Dandekar | MAZE | Common Stock | Sale | -22.2% | $205,031 | $27.34 | -7,500 | 26,250 | 29 Jul 2026 | Direct |
| Atul Dandekar | MAZE | Common Stock | Options Exercise | 28.6% | 7,500 | 33,750 | 29 Jul 2026 | Direct | ||
| Atul Dandekar | MAZE | Stock Option (Right to Buy) | Options Exercise | -25.7% | -7,500 | 21,643 | 29 Jul 2026 | Direct | ||
| Harold Bernstein | MAZE | Common Stock | Sale | -100% | $436,864 | $29.90 | -14,609 | 0 | 01 Jul 2026 | Direct |
| Harold Bernstein | MAZE | Common Stock | Options Exercise | 14,609 | 14,609 | 01 Jul 2026 | Direct | |||
| Harold Bernstein | MAZE | Stock Option (Right to Buy) | Options Exercise | -7.04% | -14,609 | 192,945 | 01 Jul 2026 | Direct | ||
| Jason Coloma V | MAZE | Common Stock | Sale | -10% | $956,527 | $29.98 | -31,908 | 287,171 | 01 Jul 2026 | Coloma Family Trust |
| Jason Coloma V | MAZE | Common Stock | Sale | -10% | $77,726 | $29.98 | -2,593 | 23,337 | 01 Jul 2026 | The Coloma 2021 Irrevocable Trust |
| Atul Dandekar | MAZE | Common Stock | Sale | -22.2% | $210,150 | $28.02 | -7,500 | 26,250 | 29 Jun 2026 | Direct |
| Atul Dandekar | MAZE | Common Stock | Options Exercise | 28.6% | 7,500 | 33,750 | 29 Jun 2026 | Direct | ||
| Atul Dandekar | MAZE | Stock Option (Right to Buy) | Options Exercise | -20.5% | -7,500 | 29,143 | 29 Jun 2026 | Direct | ||
| Jason Coloma V | MAZE | Common Stock | Sale | -6.96% | $621,674 | $26.05 | -23,865 | 319,079 | 23 Jun 2026 | Coloma Family Trust |
| Jason Coloma V | MAZE | Common Stock | Sale | -7.29% | $53,040 | $26.00 | -2,040 | 25,930 | 22 Jun 2026 | The Coloma 2021 Irrevocable Trust |
| Jason Coloma V | MAZE | Common Stock | Sale | -0.57% | $50,781 | $26.00 | -1,953 | 342,944 | 22 Jun 2026 | Coloma Family Trust |
| Daniel K. Spiegelman | MAZE | Stock Option (Right to Buy) | Award | 18,000 | 18,000 | 08 Jun 2026 | Direct | |||
| Richard H. Scheller | MAZE | Stock Option (Right to Buy) | Award | 18,000 | 18,000 | 08 Jun 2026 | Direct | |||
| Jonathan E. Lim | MAZE | Stock Option (Right to Buy) | Award | 18,000 | 18,000 | 08 Jun 2026 | Direct | |||
| Herve Hoppenot | MAZE | Stock Option (Right to Buy) | Award | 18,000 | 18,000 | 08 Jun 2026 | Direct | |||
| Charles J. Homcy | MAZE | Stock Option (Right to Buy) | Award | 18,000 | 18,000 | 08 Jun 2026 | Direct |
* marks a reported price that did not pass the local price check.